NCT07667829
Vasopressor Agents in Pulmonary Hypertension Crisis
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Eligibility criteria expanded, about 15 words
- Start date changed from estimate of Jun 2026 to Aug 19, 2026
- Site details revised at 3 of 3 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
The initial dose is 0.02 mg/kg/min of norepinephrine; each dose adjustment (increase or decrease) is 0.02 mg/kg/min of norepinephrine; the maximum dose of norepinephrine is 0.2 mg/kg/min.
The initial dose is 2 μg/kg/min of dopamine; each dose adjustment (increase or decrease) is 2 μg/kg/min of dopamine; the maximum dose of dopamine is 20 μg/kg/min.
The initial dose is 0.02 μg/kg/min of epinephrine; each adjustment (increase or decrease) is 0.02 μg/kg/min of epinephrine; the maximum dose of epinephrine is 0.2 μg/kg/min
Drugs: Norepinephrine, Dopamine, Epinephrine
Sites
3 sites in 1 country